Primary and secondary long-term prophylaxis of thromboembolism in outpatients with the low-molecular-weight heparin Kabi 2165.
Bleeding episodes and other side effects may complicate the treatment with oral anticoagulants. We report on the results of 66 patients who were treated with a low molecular weight heparin fraction for up to 19 months. The data of the study demonstrate the effective long-term anticoagulation with low-molecular-weight heparin and the reduced incidence of hemorrhages compared with conventional anticoagulants. Thus, low-molecular-weight heparin may be effectively and safely used for long-term anticoagulation in patients with bleeding problems on conventional anticoagulants.